Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
17 hedge funds and large institutions have $683K invested in Cyclo Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
21% more funds holding
Funds holding: 14 → 17 (+3)
6% less capital invested
Capital invested by funds: $725K → $683K (-$42.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.3K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$19.8K |
| 3 |
VF
Virtu Financial
New York
|
+$16.5K |
| 4 |
State Street
Boston,
Massachusetts
|
+$6K |
| 5 |
JP Morgan Chase
New York
|
+$369 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$28K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$6.15K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.37K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$569 |
CYTH Hedge Fund Activity: Q3 2023 in Review
17 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q3 2023, worth a combined $683K — down 5.8% from $725K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CYTH positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $33.3K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $28K sold.
- 17 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q3 2023, up from 14 in Q2 2023.
- Funds reported $683K of Cyclo Therapeutics, Inc. Common Stock stock for Q3 2023, down 5.8% quarter-over-quarter.
- 4 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of +3 holders.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q3 2023 was Vanguard Group, an estimated $33.3K added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q3 2023 was Renaissance Technologies, an estimated $28K sold.
Based on aggregated 13F filings for Q3 2023.